REATA PHARMACEUTICALS INC Proceeds from Common Stock Issued
REATA PHARMACEUTICALS INC reported Proceeds from Common Stock Issued of $1.00 thousand for the 3-month period ending 2023-03-31, per its 10-Q filed 2023-05-10.
Discontinued › Cash Flow › Financing Activities
us-gaap:ProceedsFromIssuanceOfCommonStock · last filed 2023-05-10
- REATA PHARMACEUTICALS INC proceeds from issuance of common stock for the quarter ending 2023-03-31 was $1.00K.
- REATA PHARMACEUTICALS INC proceeds from issuance of common stock for the quarter ending 2022-03-31 was $0.00.
- REATA PHARMACEUTICALS INC proceeds from issuance of common stock for the quarter ending 2021-12-31 was $0.00, a 100.00% decline year-over-year.
- REATA PHARMACEUTICALS INC proceeds from issuance of common stock for the quarter ending 2021-09-30 was $0.00.
- REATA PHARMACEUTICALS INC proceeds from issuance of common stock for fiscal 2022 was $0.00.
- REATA PHARMACEUTICALS INC proceeds from issuance of common stock for fiscal 2021 was $0.00, a 100.00% decline from fiscal 2020.
- REATA PHARMACEUTICALS INC proceeds from issuance of common stock for fiscal 2020 was $333.28M, a 32.32% decline from fiscal 2019.
- REATA PHARMACEUTICALS INC proceeds from issuance of common stock for fiscal 2019 was $492.45M, a 110.90% increase from fiscal 2018.
| Period end | Proceeds from Issuance of Common Stock 3 month | Proceeds from Issuance of Common Stock 6 month | Proceeds from Issuance of Common Stock 9 month | Proceeds from Issuance of Common Stock 12 month |
|---|---|---|---|---|
| 2023-03-31 | $1.00K 10-Q · filed 2023-05-10 | |||
| 2022-12-31 | $0.00 10-K · filed 2023-02-24 | |||
| 2022-03-31 | $0.00 10-Q · filed 2023-05-10 | $0.00 derived: sum of 2 quarters · filed 2023-05-10 | $0.00 derived: sum of 3 quarters · filed 2023-05-10 | |
| 2021-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2023-02-24 | $0.00 derived: sum of 2 quarters · filed 2023-02-24 | $0.00 10-K · filed 2023-02-24 | |
| 2021-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-08 | $0.00 10-Q · filed 2021-11-08 | ||
| 2021-06-30 | $0.00 10-Q · filed 2021-08-09 | |||
| 2020-12-31 | $277.88M derived: 10-K 12 month − 10-Q 9 month · filed 2023-02-24 | $277.88M derived: sum of 2 quarters · filed 2023-02-24 | $333.28M 10-K · filed 2023-02-24 | |
| 2020-09-30 | -$1.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-08 | $55.40M 10-Q · filed 2021-11-08 | ||
| 2020-06-30 | $55.40M 10-Q · filed 2021-08-09 | |||
| 2019-12-31 | $492.45M derived: 10-K 12 month − 10-Q 9 month · filed 2022-02-28 | $492.45M derived: sum of 2 quarters · filed 2022-02-28 | $492.45M 10-K · filed 2022-02-28 | |
| 2019-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2020-11-09 | $0.00 10-Q · filed 2020-11-09 | ||
| 2019-06-30 | $0.00 10-Q · filed 2020-08-10 | |||
| 2018-12-31 | $650.00K derived: 10-K 12 month − 10-Q 9 month · filed 2021-03-01 | $233.50M 10-K · filed 2021-03-01 | ||
| 2018-09-30 | $232.85M 10-Q · filed 2019-11-12 | |||
| 2017-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2020-02-19 | $108.91M 10-K · filed 2020-02-19 | ||
| 2017-09-30 | $108.91M 10-Q · filed 2018-11-07 | |||
| 2016-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2019-02-28 | $64.70M 10-K · filed 2019-02-28 | ||
| 2016-09-30 | $64.70M 10-Q · filed 2017-11-13 |